secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2021-07-08T23:59:59+00:00
Accession:  0001564590-21-036074
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics President/CMO resigns; CEO added as President; new director appointed
--------------------------------------------------------------------------------

- Dr. Amit Rakhit resigns as President and CMO effective Aug 27, 2021; will join Scientific & Clinical Advisory Board.
- Resignation not due to disagreement with company on operations, policies, or financial matters.
- CEO Jeremy M. Levin appointed President in addition to Chairman and CEO roles, effective upon Rakhit's departure.
- Robert Michael Poole appointed Class I director effective July 9, 2021, term until 2024 annual meeting.
- Poole entitled to standard non-employee director cash and equity compensation per company policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/ovid-8k_20210708.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-036074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer